Veterinary Vaccines
Undisclosed Animal Diseases
Pre-clinicalActive
Key Facts
About Vaccizone
Vaccizone is a private, pre-clinical stage biotech founded in 2020 and headquartered in London, with significant R&D operations in Istanbul. The company's proprietary ASC technology platform utilizes a modified inflammasome complex (ASC speck) to deliver antigens, offering improved stability, enhanced delivery to antigen-presenting cells, and intrinsic adjuvant properties. Its initial pipeline includes programs for COVID-19, melanoma, and veterinary vaccines, positioning it to address significant unmet needs in vaccine development and immunotherapy.
View full company profile